CN1281621C - Method of diagnosing and treating heritage spasm paraplegia using NIPAl gene mutation hot point - Google Patents
Method of diagnosing and treating heritage spasm paraplegia using NIPAl gene mutation hot point Download PDFInfo
- Publication number
- CN1281621C CN1281621C CN 200310108710 CN200310108710A CN1281621C CN 1281621 C CN1281621 C CN 1281621C CN 200310108710 CN200310108710 CN 200310108710 CN 200310108710 A CN200310108710 A CN 200310108710A CN 1281621 C CN1281621 C CN 1281621C
- Authority
- CN
- China
- Prior art keywords
- nipa1
- gene
- seq
- leu
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- 206010064571 Gene mutation Diseases 0.000 title description 3
- 206010033892 Paraplegia Diseases 0.000 title description 3
- 208000005392 Spasm Diseases 0.000 title description 2
- 101000578262 Homo sapiens Magnesium transporter NIPA1 Proteins 0.000 claims abstract description 83
- 102100028112 Magnesium transporter NIPA1 Human genes 0.000 claims abstract description 74
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 65
- 101100348640 Homo sapiens NIPA1 gene Proteins 0.000 claims abstract description 29
- 101150057005 NIPA1 gene Proteins 0.000 claims abstract description 29
- 230000035772 mutation Effects 0.000 claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 230000008859 change Effects 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- 239000003471 mutagenic agent Substances 0.000 claims description 16
- 239000004475 Arginine Substances 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 101100043229 Oryza sativa subsp. japonica SPL14 gene Proteins 0.000 claims description 3
- 208000008675 hereditary spastic paraplegia Diseases 0.000 abstract description 40
- 238000003745 diagnosis Methods 0.000 abstract description 13
- 241000252212 Danio rerio Species 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 241001441724 Tetraodontidae Species 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 238000011820 transgenic animal model Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 26
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 239000003513 alkali Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 13
- 239000002585 base Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 230000000869 mutational effect Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 108010050848 glycylleucine Proteins 0.000 description 6
- 230000004087 circulation Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 101100256910 Drosophila melanogaster sick gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 description 3
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 3
- 241001441726 Tetraodontiformes Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 102000053724 human NIPA1 Human genes 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 108091064702 1 family Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 2
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 2
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 2
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 2
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- ZXQPJYWZSFGWJB-AVGNSLFASA-N Glu-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)N ZXQPJYWZSFGWJB-AVGNSLFASA-N 0.000 description 2
- IXKRSKPKSLXIHN-YUMQZZPRSA-N Gly-Cys-Leu Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O IXKRSKPKSLXIHN-YUMQZZPRSA-N 0.000 description 2
- COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 2
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 2
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AVQOSMRPITVTRB-CIUDSAMLSA-N His-Asn-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N AVQOSMRPITVTRB-CIUDSAMLSA-N 0.000 description 2
- WUEIUSDAECDLQO-NAKRPEOUSA-N Ile-Ala-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)O)N WUEIUSDAECDLQO-NAKRPEOUSA-N 0.000 description 2
- KEKTTYCXKGBAAL-VGDYDELISA-N Ile-His-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N KEKTTYCXKGBAAL-VGDYDELISA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 2
- PVSPJQWHEIQTEH-JYJNAYRXSA-N Met-Val-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PVSPJQWHEIQTEH-JYJNAYRXSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- AWAYOWOUGVZXOB-BZSNNMDCSA-N Phe-Asn-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 AWAYOWOUGVZXOB-BZSNNMDCSA-N 0.000 description 2
- YFXXRYFWJFQAFW-JHYOHUSXSA-N Phe-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YFXXRYFWJFQAFW-JHYOHUSXSA-N 0.000 description 2
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 2
- MHHQQZIFLWFZGR-DCAQKATOSA-N Pro-Lys-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O MHHQQZIFLWFZGR-DCAQKATOSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 2
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- CTONFVDJYCAMQM-IUKAMOBKSA-N Thr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)N CTONFVDJYCAMQM-IUKAMOBKSA-N 0.000 description 2
- LXWZOMSOUAMOIA-JIOCBJNQSA-N Thr-Asn-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O LXWZOMSOUAMOIA-JIOCBJNQSA-N 0.000 description 2
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 2
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 2
- QIVPZSWBBHRNBA-JYJNAYRXSA-N Val-Pro-Phe Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O QIVPZSWBBHRNBA-JYJNAYRXSA-N 0.000 description 2
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 210000002415 kinetochore Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- NJZHEQOUHLZCOX-ZENOOKHLSA-N (3aR,4R,9bS)-golgicide A Chemical compound C1([C@@H]2NC3=C(F)C=C(C=C3[C@H]3C=CC[C@H]32)F)=CC=CN=C1 NJZHEQOUHLZCOX-ZENOOKHLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 1
- KRHRBKYBJXMYBB-WHFBIAKZSA-N Ala-Cys-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O KRHRBKYBJXMYBB-WHFBIAKZSA-N 0.000 description 1
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- QQACQIHVWCVBBR-GVARAGBVSA-N Ala-Ile-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QQACQIHVWCVBBR-GVARAGBVSA-N 0.000 description 1
- NOGFDULFCFXBHB-CIUDSAMLSA-N Ala-Leu-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N NOGFDULFCFXBHB-CIUDSAMLSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- JPOQZCHGOTWRTM-FQPOAREZSA-N Ala-Tyr-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPOQZCHGOTWRTM-FQPOAREZSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 1
- GQRDIVQPSMPQME-ZPFDUUQYSA-N Asn-Ile-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O GQRDIVQPSMPQME-ZPFDUUQYSA-N 0.000 description 1
- HZZIFFOVHLWGCS-KKUMJFAQSA-N Asn-Phe-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O HZZIFFOVHLWGCS-KKUMJFAQSA-N 0.000 description 1
- ZAESWDKAMDVHLL-RCOVLWMOSA-N Asn-Val-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O ZAESWDKAMDVHLL-RCOVLWMOSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- PDRMRVHPAQKTLT-NAKRPEOUSA-N Cys-Ile-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O PDRMRVHPAQKTLT-NAKRPEOUSA-N 0.000 description 1
- GGRDJANMZPGMNS-CIUDSAMLSA-N Cys-Ser-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O GGRDJANMZPGMNS-CIUDSAMLSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- YRWWJCDWLVXTHN-LAEOZQHASA-N Gln-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N YRWWJCDWLVXTHN-LAEOZQHASA-N 0.000 description 1
- JRHPEMVLTRADLJ-AVGNSLFASA-N Gln-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JRHPEMVLTRADLJ-AVGNSLFASA-N 0.000 description 1
- SFAFZYYMAWOCIC-KKUMJFAQSA-N Gln-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N SFAFZYYMAWOCIC-KKUMJFAQSA-N 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- NPMSEUWUMOSEFM-CIUDSAMLSA-N Glu-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N NPMSEUWUMOSEFM-CIUDSAMLSA-N 0.000 description 1
- DMYACXMQUABZIQ-NRPADANISA-N Glu-Ser-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O DMYACXMQUABZIQ-NRPADANISA-N 0.000 description 1
- DXMOIVCNJIJQSC-QEJZJMRPSA-N Glu-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N DXMOIVCNJIJQSC-QEJZJMRPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XTQFHTHIAKKCTM-YFKPBYRVSA-N Gly-Glu-Gly Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O XTQFHTHIAKKCTM-YFKPBYRVSA-N 0.000 description 1
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 description 1
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 1
- ZLCLYFGMKFCDCN-XPUUQOCRSA-N Gly-Ser-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)CN)C(O)=O ZLCLYFGMKFCDCN-XPUUQOCRSA-N 0.000 description 1
- RIYIFUFFFBIOEU-KBPBESRZSA-N Gly-Tyr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 RIYIFUFFFBIOEU-KBPBESRZSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- ZUPVLBAXUUGKKN-VHSXEESVSA-N His-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CN=CN2)N)C(=O)O ZUPVLBAXUUGKKN-VHSXEESVSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DVRDRICMWUSCBN-UKJIMTQDSA-N Ile-Gln-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N DVRDRICMWUSCBN-UKJIMTQDSA-N 0.000 description 1
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
- QZZIBQZLWBOOJH-PEDHHIEDSA-N Ile-Ile-Val Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)O QZZIBQZLWBOOJH-PEDHHIEDSA-N 0.000 description 1
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 1
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 1
- UYODHPPSCXBNCS-XUXIUFHCSA-N Ile-Val-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C UYODHPPSCXBNCS-XUXIUFHCSA-N 0.000 description 1
- SWNRZNLXMXRCJC-VKOGCVSHSA-N Ile-Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 SWNRZNLXMXRCJC-VKOGCVSHSA-N 0.000 description 1
- OXKYZSRZKBTVEY-ZPFDUUQYSA-N Leu-Asn-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OXKYZSRZKBTVEY-ZPFDUUQYSA-N 0.000 description 1
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 1
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- QPXBPQUGXHURGP-UWVGGRQHSA-N Leu-Gly-Met Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCSC)C(=O)O)N QPXBPQUGXHURGP-UWVGGRQHSA-N 0.000 description 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
- AUBMZAMQCOYSIC-MNXVOIDGSA-N Leu-Ile-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O AUBMZAMQCOYSIC-MNXVOIDGSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- ICYRCNICGBJLGM-HJGDQZAQSA-N Leu-Thr-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O ICYRCNICGBJLGM-HJGDQZAQSA-N 0.000 description 1
- CGHXMODRYJISSK-NHCYSSNCSA-N Leu-Val-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O CGHXMODRYJISSK-NHCYSSNCSA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 1
- DTUZCYRNEJDKSR-NHCYSSNCSA-N Lys-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN DTUZCYRNEJDKSR-NHCYSSNCSA-N 0.000 description 1
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 1
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- QRHWTCJBCLGYRB-FXQIFTODSA-N Met-Ala-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(O)=O QRHWTCJBCLGYRB-FXQIFTODSA-N 0.000 description 1
- DRXODWRPPUFIAY-DCAQKATOSA-N Met-Asn-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN DRXODWRPPUFIAY-DCAQKATOSA-N 0.000 description 1
- LCPUWQLULVXROY-RHYQMDGZSA-N Met-Lys-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LCPUWQLULVXROY-RHYQMDGZSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 208000002038 Muscle Hypertonia Diseases 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- WLYPRKLMRIYGPP-JYJNAYRXSA-N Phe-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 WLYPRKLMRIYGPP-JYJNAYRXSA-N 0.000 description 1
- JMCOUWKXLXDERB-WMZOPIPTSA-N Phe-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 JMCOUWKXLXDERB-WMZOPIPTSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- COAHUSQNSVFYBW-FXQIFTODSA-N Ser-Asn-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O COAHUSQNSVFYBW-FXQIFTODSA-N 0.000 description 1
- KCFKKAQKRZBWJB-ZLUOBGJFSA-N Ser-Cys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O KCFKKAQKRZBWJB-ZLUOBGJFSA-N 0.000 description 1
- DLPXTCTVNDTYGJ-JBDRJPRFSA-N Ser-Ile-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O DLPXTCTVNDTYGJ-JBDRJPRFSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- 208000032930 Spastic paraplegia Diseases 0.000 description 1
- GKMYGVQDGVYCPC-IUKAMOBKSA-N Thr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)N GKMYGVQDGVYCPC-IUKAMOBKSA-N 0.000 description 1
- OYTNZCBFDXGQGE-XQXXSGGOSA-N Thr-Gln-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O OYTNZCBFDXGQGE-XQXXSGGOSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- NWECYMJLJGCBOD-UNQGMJICSA-N Thr-Phe-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O NWECYMJLJGCBOD-UNQGMJICSA-N 0.000 description 1
- MFMGPEKYBXFIRF-SUSMZKCASA-N Thr-Thr-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MFMGPEKYBXFIRF-SUSMZKCASA-N 0.000 description 1
- CXUFDWZBHKUGKK-CABZTGNLSA-N Trp-Ala-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O)=CNC2=C1 CXUFDWZBHKUGKK-CABZTGNLSA-N 0.000 description 1
- KBKTUNYBNJWFRL-UBHSHLNASA-N Trp-Ser-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 KBKTUNYBNJWFRL-UBHSHLNASA-N 0.000 description 1
- NXRGXTBPMOGFID-CFMVVWHZSA-N Tyr-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O NXRGXTBPMOGFID-CFMVVWHZSA-N 0.000 description 1
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 description 1
- HHSILIQTHXABKM-YDHLFZDLSA-N Val-Asp-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O HHSILIQTHXABKM-YDHLFZDLSA-N 0.000 description 1
- URIRWLJVWHYLET-ONGXEEELSA-N Val-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C URIRWLJVWHYLET-ONGXEEELSA-N 0.000 description 1
- DAVNYIUELQBTAP-XUXIUFHCSA-N Val-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N DAVNYIUELQBTAP-XUXIUFHCSA-N 0.000 description 1
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 1
- MHHAWNPHDLCPLF-ULQDDVLXSA-N Val-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=CC=C1 MHHAWNPHDLCPLF-ULQDDVLXSA-N 0.000 description 1
- YKNOJPJWNVHORX-UNQGMJICSA-N Val-Phe-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YKNOJPJWNVHORX-UNQGMJICSA-N 0.000 description 1
- MJOUSKQHAIARKI-JYJNAYRXSA-N Val-Phe-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 MJOUSKQHAIARKI-JYJNAYRXSA-N 0.000 description 1
- MIKHIIQMRFYVOR-RCWTZXSCSA-N Val-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)N)O MIKHIIQMRFYVOR-RCWTZXSCSA-N 0.000 description 1
- HOZAIQIEJTWWDG-HJOGWXRNSA-N Val-Trp-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N HOZAIQIEJTWWDG-HJOGWXRNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010376 human cloning Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200000898 rs104894496 Human genes 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 101150041303 sick gene Proteins 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 101150112970 up gene Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a process for discovering a mutation hotspot in an NIPA1 gene and two new mutations in the mutation hotspot. The mutations in the gene can cause hereditary spastic paraplegia and can be simultaneously compared with NIPA1 homologous genes of mice, rats, globefishes and zebra fish by homoeology; transcripton and translation products of the gene are useful for detection and diagnosis of the hereditary spastic paraplegia, development of iatrotechnics of the hereditary spastic paraplegia, separation and production of protein of NIPA1 mutant gene codes, and construction of transgenic animal models for expressing the mutant gene.
Description
Technical field
The present invention relates to biotechnology and medical field.More specifically, the present invention relates to utilize the method for people NIPA1 gene and coded product diagnosis and treatment hereditary spastic paraplegia, and contain NIPA1 gene and/or proteic pharmaceutical composition.
Background technology
Hereditary spastic paraplegia is the disease that is caused by the pathologic sudden change of individual gene, is one group of disease that genetic heterogeneity is very strong, and promptly this disease can be caused by heterogeneic different sudden changes.Therefore, looking for and screen this sick Disease-causing gene and mutation type thereof and be not only understanding, illustrate the pathogenetic necessary approach of this disease, also is simultaneously to set up the prerequisite of diagnosing before this sick gene diagnosis and the antenatal/plantation.After understanding this sick Disease-causing gene and mutation type thereof, just can set up gene diagnosis technology based on this gene and mutation type thereof, in the hope of suspicious clinically patient being carried out the diagnosis of conclusive gene level, can also be by the detection of amniotic fluid and bleeding of the umbilicus, judge whether fetus carries the sudden change of this gene, thereby whether can suffer from this disease after the birth of prediction fetus, and this information is offered pregnant woman and household thereof, thereby decision continues or termination of pregnancy.Owing to the sudden change of gene is this pathogenetic reason, in the long term, the gene therapy of correcting sudden change is used in the screening of sudden change, or other method at the biological effect of this sudden change (as the protein antagonist) is gone to treat this disease and is become possibility.Therefore, in the long term, this discovery has the application prospect of treatment aspect.Rainier S equals this month and has reported the T45R of NIPA1 gene (sudden change of 159C → G) can cause this disease (Rainier S, et al:NIPA1 gene mutations cause autosomal dominanthereditary spastic paraplegia (SPG6) .Am J Hum Genet, 73:967-971,2003).
Because this sick clinical diagnosis is not now had special methods, only depend on and get rid of other disease that can cause the same symptoms sign and carry out (referring to table 1), thus the diagnosis of gene level not only clear and definite the concrete position and the kind of sudden change, also have accurately, fast, low consumed characteristics.Therefore, this area presses for the effective ways of the new early diagnosis of exploitation, treatment hereditary spastic paraplegia.
Summary of the invention
The purpose of this invention is to provide morbidity or relevant polynucleotide and the albumen of onset risk with hereditary spastic paraplegia.
Another target of the present invention is to regulate the compound of these albumen or polynucleotide expression or function with these albumen and polynucleotide screening.
Further aim of the present invention is to regulate or albumen and the polynucleotide interaction relevant with described hereditary spastic paraplegia with these compounds, to treat and to diagnose this disease.
Further purpose of the present invention provides the method for controlling the diagnosing hereditary Spastic Paraplegia.
A first aspect of the present invention provides a kind of NIPA1 transgenation albumen, and described NIPA1 transgenation albumen has the aminoacid sequence shown in the SEQID NO:2, and wherein the 106th amino acids is an arginine.
A second aspect of the present invention provides a kind of isolating NIPA1 mutator gene, it is characterized in that its coding said mutation albumen.
Preferably, described NIPA1 mutator gene has the nucleotide sequence shown in the SEQ ID NO:1, wherein undergos mutation for the 341st, and its sudden change is selected from:
G→C:
G→A。
A third aspect of the present invention, a kind of method that the hereditary spastic paraplegia of individuality is diagnosed is provided, described method comprises step: detect this individual NIPA1 gene, transcript and/or albumen, and compare with normal N IPA1 gene, transcript and/or albumen, just there are differences and show that this individuality suffers from the possibility of hereditary spastic paraplegia and be higher than normal population.Preferably, detection be gene or the transcript of NIPA1, and with normal NIPA1 nucleotide sequence (SEQ ID NO:1) comparing difference.Preferable, described difference is selected from:
The 341st G → C among the SEQ ID NO:1;
The 341st G → A among the SEQ ID NO:1;
The 106th glycine becomes arginine among the SEQ ID NO:2.
A fourth aspect of the present invention provides a kind of compound, and described compound suppresses the proteic activation of above-mentioned NIPA1 transgenation or suppresses the expression of above-mentioned NIPA1 mutator gene.Preferable, described compound is the antisense nucleotide of NIPA1 mutator gene.
A fifth aspect of the present invention provides a kind of NIPA1 transgenation proteic purposes, and described NIPA1 transgenation albumen is used to prepare the composition of treatment or diagnosing hereditary Spastic Paraplegia.
A sixth aspect of the present invention provides a kind of purposes of NIPA1 mutator gene, described NIPA1 mutator gene to be used to prepare the composition of treatment or diagnosing hereditary Spastic Paraplegia.
A seventh aspect of the present invention provides a kind of test kit that detects hereditary spastic paraplegia, and described test kit comprises the primer of specific amplification NIPA1 gene or transcript.Preferable described test kit also contains the reagent that is selected from down group:
(a) with mutable site bonded probe;
(b) restriction enzyme in identification mutational site.
Be selected from the sudden change described in the preference:
The 341st G → C among the SEQ ID NO:1;
The 341st G → A among the SEQ ID NO:1;
The 106th glycine becomes arginine among the SEQ ID NO:2.
The present invention has also comprised the compound of using described albumen and polynucleotide screening treatment and/or diagnosing hereditary Spastic Paraplegia, and these compounds can be used as the activator or the antagonist of NIPA1 genetic expression or function.Both as the target of SCREENED COMPOUND, for synthetic derivative compound provides raw material, the latter can be as the activator or the antagonist of NIPA1 genetic expression or function simultaneously for these albumen and polynucleotide.
Especially, the present invention also comprises the unconventionality expression level at NIPA1 gene or gene product, the sudden change of gene even the detection method of aberrant gene or gene product.Above-mentioned coming across unusually has hereditary spastic paraplegia or has in people's the cell or tissue of hereditary spastic paraplegia onset risk, perhaps in the cell of suffering from this disease or animal model.
Thereby the present invention is used for by detecting the onset risk that NIPA1 gene or gene product instruct screening patients with hereditary spastic paraplegia or hereditary spastic paraplegia.The detection of unconventionality expression level, transgenation or other unusual phenomenon allowed the risk of patients with hereditary spastic paraplegia or hereditary spastic paraplegia morbidity is diagnosed.In one embodiment, the detection of passing through abnormal level, transgenation or other unusual phenomenon of NIPA1 gene has been indicated in this invention.
Therefore, the present invention also comprises suffering from hereditary spastic paraplegia, or the people's of hereditary spastic paraplegia onset risk methods of treatment arranged, present method is with unconventionality expression level, sudden change or other the unusual phenomenon of NIPA1 gene or gene product index or the target as treatment.
The present invention has also comprised with NIPA1 gene or gene product and regulates the factor of expression level as index or target screening or effectively reverse sudden change in NIPA1 gene or gene product or the method for other off-notes.Therefore, the present invention includes screening NIPA1 gene or the activator of gene product and the method for antagonist.These factors can be used for diagnosis or treatment hereditary spastic paraplegia to the expression level of NIPA1 gene or gene product or the influence of function according to them.The expression of NIPA1 gene or gene product or the factor of function be can regulate by differentiating, just expression level by regulating NIPA1 gene or gene product or hereditary spastic paraplegia pathogenic process that function influences a people or the method for occurring degree obtained.Further, by obtaining the factor that these genetic expressions are regulated, just formed the method for the result of treatment of assessment pair cell and animal model.
Can interact by screening, perhaps allow the factor that unconventionality expression or function to NIPA1 gene or gene product detect, so just form the morbidity of diagnosing hereditary Spastic Paraplegia or the method for onset risk.
The present invention has further comprised the composition that obtains on NIPA1 gene or gene product basis, they are all very useful for the expression or the function that detect or regulate NIPA1 gene or gene product.So these compositions are very useful for diagnosis and/or treatment hereditary spastic paraplegia.
The present invention has also comprised cell and the animal model according to NIPA1 gene in the model or gene product research hereditary spastic paraplegia.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
Description of drawings
Fig. 1. family 1 D15S1021~D15S1002 mark monoploid analytical results.
Black pattern symbolic representation patient, the rectangular representative pathology of black monoploid.The box indicating male sex, circle is represented the women.Reorganization has appearred in IV-7, V-1 and V-7 among the kinsfolk.
Fig. 2. family 2 pedigrees.
Distance between 2 linkage analysis Lod of Fig. 3 .D15S1021~D15S1002 Scores value and polymorphism mark (family 1).
The cDNA sequence of Fig. 4 .NIPA1.
The sudden change that the contriver finds is the sudden change of the 341st alkali base in this sequence, and the alkali base of this position has added frame)
Fig. 5: patient's forward sequencing result in the family 1 (arrow is depicted as the mutational site, G → C).
Fig. 6: patient's backward sequencing result in the family 1 (arrow is depicted as the mutational site, C → G).
Fig. 7: normal people's forward sequencing result (arrow is depicted as the place, mutational site, but does not undergo mutation, and is G) among normal people and the crowd in the family 1.
Fig. 8: normal people's backward sequencing result (arrow is depicted as the place, mutational site, but does not undergo mutation, and is C) among normal people and the crowd in the family 1.
Fig. 9: patient's forward sequencing result in the family 2 (arrow is depicted as the mutational site, G → A).
Figure 10: patient's backward sequencing result in the family 2 (arrow is depicted as the mutational site, C → T).
Figure 11: the sequence alignment result of human NIPA1 gene and mouse nipal gene.
Grayish alkali basis representation sudden change place codon, what add a horizontal line down is the place, mutational site.The result shows that this codon is identical in mouse and people.
Figure 12: the sequence alignment result of human NIPA1 gene and rat nipal gene.
Grayish alkali basis representation sudden change place codon, what add a horizontal line down is the place, mutational site.The result shows that this codon is identical in rat and people.
Figure 13: the sequence alignment result of human NIPA1 gene and zebra fish (zebrafish) gene.
Grayish alkali basis representation sudden change place codon, what add a horizontal line down is the place, mutational site.The result shows that this codon is identical in zebra fish and people.
Figure 14: the comparison result of the amino acid of human NIPA1 genes encoding and mouse, filefish aminoacid sequence.
Place, box indicating mutational site amino acid.Comparison result shows is at mouse, filefish (Fugul), philtrum, and this site all is glycine (Glysine).
The biological structure prognostic chart of Figure 15: NIPA1.
329 in the total amino acid of the proteic aminoacid sequence of NIPA1, the contriver is divided into four sections arrangements to it in this figure:
1. the first line number word of each section is the amino acid counting of this Argine Monohydrochloride sequence.
2. second of each section row is this proteic aminoacid sequence.
3. the M of the third line of each section represents that this place may be a cross-cell membrane functional domain (transmembranemotif), and the whole piece sequence has 8 possible cross-cell membrane functional domains.
4. the O of the fourth line of each section, M, i represent the possible film outside part (outsiceregion) of this aminoacid sequence respectively, stride part (inside region) in membrane portions (membrane helix) and the film.
The new mutant that the contriver finds is positioned at the 106th of this aminoacid sequence, is the change from glycine (G) to arginine (R), underlines in the drawings.
Embodiment
NIPA1 mutain of the present invention is meant the albumen with the aminoacid sequence shown in the SEQ ID NO:2, and wherein the 106th amino acids is an arginine.NIPA1 mutator gene coding NIPA1 mutain of the present invention.It has the nucleotide sequence shown in the SEQ ID NO:1, wherein undergos mutation for the 341st.Preferable, said mutation is selected from:
G→C:
G→A。
People NIPA1 Nucleotide full length sequence of the present invention (NIPA1 mutator gene) or its fragment can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be according to the relevant nucleotide sequence of NIPA1, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.
In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This is normally with its human cloning carrier; Change cell again over to; Separate from the host cell after the propagation by ordinary method then and obtain relevant sequence.
In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually by earlier synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.
NIPA1 encoding sequence of the present invention is inserted suitable expression vector, change host cell again over to, just can isolate the NIPA1 mutain.
The present invention also comprises NIPA1 mutator gene of the present invention or the albumen of its fragment coding has specific polyclonal antibody and monoclonal antibody, especially monoclonal antibody.Here, " specificity " is meant that antibody capable is incorporated into people NIPA1 mutator gene product or fragment.Preferably, refer to that those can combine with people NIPA1 mutator gene product or fragment but nonrecognition and be incorporated into the antibody of other irrelevant antigen molecule.
This type of monoclonal antibody can utilize hybridoma technology to prepare.Antibody of the present invention comprises the antibody that can block people NIPA1 mutain function and the antibody that does not influence people NIPA1 protein function.Each antibody-like of the present invention can utilize the fragment or the functional zone of people NIPA1 mutator gene product, obtains by the routine immunization technology.These fragments or functional zone can utilize recombinant methods or utilize the albumen synthesizer synthetic.
The present invention includes NIPA1 mutain and antibody thereof, inhibitor, agonist, antagonist etc.When in treatment, using (administration), can provide different effects.Usually, can these materials are formulated in nontoxic, inert and the pharmaceutically acceptable aqueous carrier medium, wherein pH is about 5 usually, and preferably pH is about 6-8, although the pH value can be with being changed to some extent by preparation Substance Properties and illness to be treated.The pharmaceutical composition for preparing can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intravenously, subcutaneous or topical (comprising affected area).Be preferably topical.
The present invention also provides a kind of pharmaceutical composition, and it contains antagonist and the pharmaceutically acceptable carrier or the vehicle of the NIPA1 mutain of the present invention of safe and effective amount.This class carrier comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.When making pharmaceutical composition, be that antagonist antagonist with the NIPA1 mutain of safe and effective amount is applied to Mammals, wherein the safety significant quantity is usually at least about 0.1 microgram/kg body weight, and in most of the cases be no more than about 10 mg/kg body weight, preferably this dosage is about 0.1 microgram/kg body weight one about 100 micrograms/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
The invention still further relates to the diagnostic testing process of quantitative and detection and localization people NIPA1 mutain level.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.
The method that whether has the NIPA1 mutain in a kind of test sample is to utilize the proteic specific antibody of NIPA1 to detect, and it comprises: sample is contacted with the NIPA1 protein specific antibody; Observe whether form antibody complex, formed antibody complex and just represented to exist in the sample NIPA1 mutain.
The proteic polynucleotide of NIPA1 can be used for the diagnosis and the treatment of NIPA1 protein related diseases.Aspect diagnosis, the proteic polynucleotide of NIPA1 can be used for detecting the proteic expression of NIPA1 NIPA1 abnormal exprssion whether or under morbid state.Can be used for the hybridization of biopsy specimen to judge the proteic abnormal expression of NIPA1 as the NIPA1 dna sequence dna.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA one polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of NIPA1 albumen and also can detect the proteic transcription product of NIPA1.
The invention provides the whether unusual method of a kind of people of detection NIPA1 genetic expression; It comprises step: (a) determine the 341st Nucleotide in sequence shown in the SEQ ID of the people NIPA1 gene NO:1; And b) detects the missense mutation that whether has alkali base G in described position.
The sudden change that detects the NIPA1 gene also can be used for the diagnosing hereditary Spastic Paraplegia.Detection can be at DNA, also can be at genomic dna.The form of NIPA1 protein mutation comprises that the point mutation compared with normal wild type NIPA1 dna sequence dna, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
The contriver has collected two hereditary spastic paraplegia patients' big family, and has used the karyomit(e) sections that full genome scanning, linkage analysis technology are positioned Disease-causing gene 15q11.1-q12 first through extensive and deep research.The contriver has carried out the detection of NIPA1 transgenation in a big family (family 1) that contains 3 generations, 14 these patients (still survive and algebraically and patient's number of blood sample are arranged), and the method by order-checking, found the sudden change of the 106th codon G → C (G106R) that this is at first screened by the contriver in the world.Simultaneously, the contriver also contains (family 2) in 3 generations, 7 patients' (still survive and the numeral of blood sample is arranged) the family at another and has found to be positioned at G → A of same alkali base and change.These two kinds of changes are G106R at amino acid levels.This makes the neutral hydrophobicity glycine (Glycine) in the peptide chain become alkaline hydrophilic arginine (Arginine).Because mutating acid is arranged in the functional group that the coding peptide chain is striden the film district, it is unusual that this change makes that the function of NIPA1 coded by said gene peptide chain takes place, thereby cause this disease.The conservative property of sudden change alkali base G in vertebrates also proved the importance of this alkali base on function.Because the sudden change of NIPA1 gene betides same alkali base site in the family of these 2 consanguinity-less relations, and the alkali base difference after the sudden change, show that this Nucleotide is the mutantional hotspot of Ben Jiyin.On this basis, the contriver has finished the present invention.
The present invention has found an intragenic mutantional hotspot of NIPA1 and has been positioned at 2 new mutants of this focus.This discovery can be applicable to hereditary spastic paraplegia diagnosis, the treatment in; And confirmed that further the NIPA1 gene is the disease gene that causes hereditary spastic paraplegia.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only are used to illustrate the present invention, limit the scope of the invention and be not used in.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
1. family is collected
By patient (McDermott CJ, White k, the et al:Hereditaryspastic paraparesis:a review of new developments.J Neurol Neurosurg Psychiary2000 in the improvement Harding standard screening family; 69:150-160).Two family patients' phenotype all is simple form, symptoms (family 1 phenotype sees Table 1, and pedigree is seen Fig. 1, and family 2 pedigrees are seen Fig. 2) such as no dysnoesia, cerebellum symptom, deafness, eye.Two familys provide by the one attached Song Chun doctor of institute of Harbin Medical University.After all family member's informed consents, get peripheral blood in the EDTA pipe.
Case | Sex | Age | Age of onset | Paraplegia | Gait changes | Quadriceps reflex is hyperfunction | Hypermyotonia | Hot-tempered spasm | Babinski sign | chadolock |
III-2 | The woman | 72 | 25 | + | + | +++ | +++ | + | + | + |
III-5 | The woman | 63 | 16 | + | + | +++ | +++ | + | + | + |
IV-2 | The woman | 56 | 30 | - | + | ++ | ++ | + | + | + |
IV-4 | The woman | 51 | 35 | - | + | ++ | ++ | + | + | + |
IV-6 | The woman | 37 | 30 | - | + | ++ | ++ | + | + | + |
IV-9 | The woman | 52 | 24 | + | + | +++ | +++ | + | + | + |
IV-14 | The man | 44 | 25 | - | + | ++ | ++ | + | + | + |
V-1 | The man | 33 | 15 | - | + | + | ++ | + | + | + |
V-2 | The woman | 31 | 25 | - | + | + | ++ | + | + | + |
V-3 | The woman | 31 | 30 | - | + | ++ | + | - | + | + |
V-4 | The man | 28 | 25 | - | + | ++ | ++ | - | + | + |
V-5 | The man | 26 | 20 | - | + | + | + | + | + | + |
V-6 | The man | 26 | 13 | - | - | + | + | - | + | + |
V-9 | The man | 26 | 20 | - | + | ++ | + | - | + | + |
The individual disease phenotype of getting involved in table 1 family
2.DNA extract
The QIAamp DNA Blood Maxi Kits that produces with Qiagen company extracts DNA from anticoagulation cirumferential blood, TE dissolving ,-70 ℃ of preservations.
3. full genome scanning
1. polymorphism mark primer sequence: be 400 little satellite repeat sequence primers of the polymorphism dinucleotide of from Genethon human inheritance collection of illustrative plates, selecting, fluorescent mark.Every pair of marker spacing is about 10cM, and ordering and the distance of the used polymorphism mark of linkage analysis on karyomit(e) comes from
Http:// www.marshfieldclinic.org/The website data.
2. PCR reaction conditions: 5-μ l reaction system contains 50ng of DNA, 2.5mM MgCl
2, 10mM Tris-HCl pH8.3,50mM KCl, 250mM each dNTP, 0.625pmol primer and the 0.25 Hotstart Taq of unit archaeal dna polymerase (QIANGEN GmbH, Hilden, Germany).Perkin-Elmer 9700 thermal cyclers are adopted in reaction.Employing standard Touchdown program: 95 ℃ of pre-sex change 12 minutes: Touchdown circulation 14 times, 95 ℃ of sex change 30 seconds, annealing temperature 1 minute, by 63 ℃ initial, each circulation is later on successively decreased 0.5 ℃, up to 56 ℃, 72 ℃ were extended 1 minute and 30 seconds; Keeping annealing temperature afterwards is 56 ℃, 1 minute, carries out 30 circulations again; Final product extended 10 minutes for 72 ℃.
3. genotype screening: the PCR product carries out genotype screening on ABI377 or 3100 sequenators, with GeneScan, and Genotyper software analysis result.
4. linkage analysis
2 linkage analysises: adopt LINKAGE software (Version 5.10), suppose that the Disease-causing gene frequency is 10
-4, the gene frequency of polymorphism mark equates that men and women's recombination fraction equates, penetrance 0.9.2 linkage analysis results obtain maximum Led Score value (Zmax): 4.55, and recombination fraction (e) is 0.The Led Score value of adjacent several polymorphism marks also greater than 3.0 (table 2, Fig. 3).
Marker polymorphism mark | LOD SCORE | Zmax at | θ= |
θ=0.00 0.01 0.05 0.10 0.20 0.30 0.40 | |||
D15S1021 D15S128 D15S646 D15S210 D15S122 D15S986 D15S97 D15S822 D15S975 D15S156 D15S1002 | 4.55 4.51 4.27 3.89 2.96 1.89 0.74 2.92 2.87 2.67 2.41 1.83 1.20 0.55 2.48 2.45 2.32 2.13 1.69 1.19 0.63 4.55 4.51 4.27 3.89 2.96 1.89 0.74 4.34 4.32 4.15 3.82 2.97 1.94 0.81 4.04 3.98 3.71 3.36 2.60 1.75 0.82 3.42 3.43 3.36 3.18 2.63 1.91 1.02 -1.02 1.08 1.66 1.74 1.48 1.0 0.45 -2.59 -0.31 0.29 0.47 0.51 0.40 0.22 0.04 0.17 0.41 0.52 0.53 0.39 0.19 -6.72 -2.20 -0.65 -0.05 0.36 0.37 0.22 | 4.55 2.92 2.48 4.55 4.34 4.04 3.43 1.74 0.51 0.53 0.37 | 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.10 0.20 0.20 0.30 |
Table 2 D15S1021~2 linkage analysis results of D15S1002 polymorphism mark
5. Fine Mapping and monoploid make up
Behind the positive chain site of preliminary acquisition, according to Genome Datebase and Genethon, database datas such as Whitehead InstitutePhysicai Map are done the intensive scanning of trying one's best with all known polymorphism marks in this sections, and method is the same.From making up, monoploid seeks possible reorganization (cross-over) simultaneously, in the hope of shortening the zone at candidate gene place to greatest extent.Monoploid makes up ordering and the distance of polymorphism mark on karyomit(e) and also comes from
Http:// www.marshfieldclinic.org/The website data.Family 1 is still survived and had the monoploid of 3 generations of blood sample, 34 individualities analyze to find, reorganization between homologous chromosomes appears respectively in IV-7, V-1 and V-7 individuality, but do not find reorganization in the kinetochore direction, therefore, the crucial sections of Disease-causing gene is between No. 15 karyomit(e) kinetochores and D15S97 in about 9.85cM zone (Fig. 1).
Its mRNA complete cDNA sequence from GeneBank (accession number BK001020) (Fig. 4) for NIPA1 gene (Homo sapiens non-imprinted in Prader-Willi/Angleman syndrom 1).The genomic dna sequence dna from
Http:// genome.ucsc.edu
Key step:
1.PCR amplification: the PCR reaction volume is 50 μ l, includes 50mmol/L Tris-HCl (pH8.8), 16.6mmol/L (NH
4)
2SO
4, 0.10mg/mlBSA, 3.0mmol/L MgCl
2, 200 μ mol/L dNTPs, each 0.2 μ mol/L of primer P1, P2, Taq enzyme 2U (MBI company), about 0.1~0.7 μ g of human gene group DNA.PCR reaction conditions: 94 ℃ of 3min:94 ℃ of 45s, 60 ℃ of 1min, 72 ℃ of 1min, 35 circulations; Last 72 ℃ are extended 10min.The sequence of primer P1 (SEQ ID NO:3) is: 5 '-GTG CTG CGC CCA TTT CAG TCA-3 ', the sequence of P2 (SEQ ID NO:4) is: 5 '-GTG CCA TCT CAACTC ACT GCA-3 '.
2. sequencing reaction scheme:
(1) pre-reaction: reaction volume is totally 3 μ l, includes PCR product 5-10ng (about 0.5-1.0 μ l), and shrimp alkaline phosphotase (SAP), each 0.25 μ l (USB company) of excision enzyme I (Exo I) mend ultrapure water to 3 μ l.Reaction mixture reacts on the PCR instrument, and 37 ℃ of temperature are bathed 15min, 85 ℃ of 15min inactivators then.Reacting the afterreaction mixture that finishes directly uses as the template of sequencing reaction.
(2) sequencing reaction: 96 orifice plates with ABI company, carry out on GeneAmp 9700 PCR instrument.Reaction volume is totally 10 μ l, includes the pre-reaction product of 3 μ l, 5 * buffer of 2 μ l, the Big-Dye of 1 μ l (ABI), 1 μ l primer (3.2pmol/ μ l), the ultrapure water of 3 μ l.Reaction conditions: 98 ℃ of 2min:96 ℃ of 10s, 50 ℃ of 5s, 60 ℃ of 4min, 30 circulations; Last 4 ℃ of preservations.
(3) order-checking purifying: directly on 96 orifice plates, carry out.
A) after sequencing reaction finished, each sample added 90 μ l75% ethanol, sticks and seals aluminium foil, the whirlpool mixing;
B) room temperature lucifuge 20min;
C) 20 ℃, the centrifugal 30min of 3500rpm (carrying out on the 5810R whizzer);
D) remove supernatant, tip upside down on four layers of thieving paper the centrifugal 30s of 350rpm;
E) room temperature lucifuge 20min is to dry ethanol;
F) every sample adds 10 μ l ultrapure waters, and last ABI3100 sequenator checks order.
3. sequencing result analysis: analyze with the ABI sequence analysis software
The contriver has found the sudden change of the 341st alkali base (cDNA sequence) G → C in family 1, found the sudden change of same site G → A in family 2.2 sudden changes all are arranged in NIPA1 gene the 3rd exon, and these 2 kinds of changes all cause the 106th amino acid to become alkaline hydrophilic arginine by the hydrophobic glycine of neutrality.So this sudden change is G341C (family 1) or G341A (family 2) on the cDNA level; In total length genomic sequence is that G25596C (family 1) or G25596A (family 2) change; Being G106R in amino acid levels two familys changes.
The contriver is to the patient of totally 14 blood samples of still surviving and adopted and 37 non-patients have all carried out forward and reverse order-checking in the family 1.All patients all contain G → C in this mutantional hotspot (G341C, G106R) (Fig. 5 Fig. 6) changes, and this sudden change and disease phenotype be divided into from.And all non-patients all do not contain this sudden change (Fig. 7,8) in the family.
The contriver is also to still surviving in the family 2 and having 7 patients of blood sample and the normal people of 13 blood samples of still surviving and have to carry out two-way order-checking.All patients all contain G in the mutantional hotspot → A change (G341A, G106R) (Fig. 9, Figure 10) and the normal people does not have this change (chart saves).
The contriver also checks order to 100 normal peoples with this family consanguinity-less relation, does not also contain this sudden change (Fig. 7,8) entirely.
1. the homology of the nucleotide sequence of human NIPA1 and mouse, rat comparison is undertaken by the Comparative Sequence among the http://genome.ucsu.edu/ of website.
2. the sequence analysis of the amino acid sequence of human NIPA1 and filefish, mouse is with reference to the people's such as Chai JH article " Identification of four highly conserved genes between breakpoint hotspots BP1 andBP2 of the Prader-Willi/Angleman syndromes deletion region that have undergoneevolutionary transposition mediated by flanking duplicons " Am J Hum Genet 2003; The comparison result of 73:898-925.
3. the homology of the aminoacid sequence of the sequence of human NIPA1, NIPA1 and zebra fish comparison utilizes software clustalx to carry out, and corresponding Nucleotide of zebra fish and aminoacid sequence derive from the website
Http:// www.ensembl.org
The result is presented in the animal of all comparisons and is equivalent to the 341st alkali base of human NIPA1 gene cDNA, and promptly first alkali base of No. 106 codon is G, and the coded amino acid of codon is glycine (Figure 11-14) entirely.The high conservative of this alkali base in organic evolution illustrated that it has important biological function in the coding peptide chain.
Utilize website http://www.embl-heidelberg.de/predictprotein/predictprotein.htm l to carry out, and examine with software TMHMM2.0.The aminoacid sequence of corresponding N IPA1 obtains from website http://www.ncbi.nlm.nih.gov.
The glycine that studies show that the 106th codon (GGG) coding of the biological structure of NIPA1 genes encoding peptide chain is arranged in the 2nd and strides film district functional group, is arranged in alpha-helix, so have important biological function (seeing Figure 15).And the glycine (GGG) that sudden change is caused is to arginine (CGG, family 1; AGG family 2)) change has obviously changed the normal physiological function of this functional group, thereby causes clinically symptom, sign.
The preparation of embodiment 5 hereditary spastic paraplegia detection kit
Prepare a test kit, it contains:
Title sequence (5 ' → 3 ') numbering concentration
Forward primer GTG CTG CGC CCA TTT CAG TCA SEQ ID NO:3 dry powder 2 OD
Reverse primer GTG CCA TCT CAA CTC ACT GCA SEQ ID NO:4 dry powder 2 OD
The PCR reaction solution contains Taq enzyme, dNTP, magnesium ion, PCR reaction buffer
PCR product purification box contains the solution of PCR product purification in a small amount, DNA adsorption column Labell
Sequencing reaction liquid contains Big Dye
Extract patients'blood 3ml to be detected, use ordinary method (or using specific test kit) from blood, to extract DNA.PCR primer in the hereditary spastic paraplegia detection kit is diluted to 0.2 μ mol/L, is that template is carried out the PCR reaction with the primer that is provided with the DNA that is extracted.Use the PRC product purification box that detection kit provided that the PCR product is carried out purifying.The product of purifying is carried out directly checking order behind the sequencing reaction.Whether the resulting sequence of observation order-checking has missense mutation.
The antagonist of NIPA1 mutain and common ointment material are pressed specific mixed, make the ointment of the antagonist that contains the NIPA1 mutain.During use, ointment is imposed on the affected part, the affected part coded mutain of NIPA1 mutator gene is suppressed, and makes patient owing to the hereditary spastic paraplegia that the coded normal protein of shortage NIPA1 causes is alleviated, until last disappearance.Or the mutain that the NIPA1 mutator gene is coded makes injection, during use subcutaneous injection carried out in the affected part, directly suppresses the NIPA1 mutain of affected area, patient's hereditary spastic paraplegia symptom improved, thereby reach the purpose of treatment.
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Sequence table
<110〉Zhongshan University
<120〉utilize NIPA1 transgenation focus to diagnose, treat the method for hereditary spastic paraplegia
<130>031112
<160>4
<170>PatentIn version 3.1
<210>1
<211>6565
<212>DNA
<213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(26)..(1015)
<223>
<400>1
ggctcggagg gcgggcgcgg gcgga atg ggg act gca gct gcg gca gcg gcg 52
Met Gly Thr Ala Ala Ala Ala Ala Ala
1 5
gcg gcg gcg gcg gcg gcg gcc ggg gag ggg gcg cgt agc ccg agc ccc 100
Ala Ala Ala Ala Ala Ala Ala Gly Glu Gly Ala Arg Ser Pro Ser Pro
10 15 20 25
gcc gcc gtg tcg ctc ggc ctg ggc gtg gcc gtc gtg tcg agc ctg gtg 148
Ala Ala Val Ser Leu Gly Leu Gly Val Ala Val Val Ser Ser Leu Val
30 35 40
aac ggg tcc acg ttc gtg cta cag aag aag ggc atc gtg cgt gcc aag 196
Asn Gly Ser Thr Phe Val Leu Gln Lys Lys Gly Ile Val Arg Ala Lys
45 50 55
cgg cga ggt act tcc tat tta aca gac att gtg tgg tgg gct ggc aca 244
Arg Arg Gly Thr Ser Tyr Leu Thr Asp Ile Val Trp Trp Ala Gly Thr
60 65 70
atc gca atg gct gtt ggc cag att gga aac ttc ctg gct tac acg gcg 292
Ile Ala Met Ala Val Gly Gln Ile Gly Asn Phe Leu Ala Tyr Thr Ala
75 80 85
gtc ccc acg gtc ctg gta acc ccc ctg ggc gcc ctt gga gta ccg ttc 340
Val Pro Thr Val Leu Val Thr Pro Leu Gly Ala Leu Gly Val Pro Phe
90 95 100 105
ggg tcc att tta gct tcc tat ctc ctg aag gaa aag ctc aac atc ttg 388
Gly Ser Ile Leu Ala Ser Tyr Leu Leu Lys Glu Lys Leu Asn Ile Leu
110 115 120
ggc aag ttg ggg tgc ctg cta agc tgt gca ggc tcc gtc gtg ctg att 436
Gly Lys Leu Gly Cys Leu Leu Ser Cys Ala Gly Ser Val Val Leu Ile
l25 130 135
atc cac tcc cca aag tct gag agt gtg acg act cag gct gag ctg gag 484
Ile His Ser Pro Lys Ser Glu Ser Val Thr Thr Gln Ala Glu Leu Glu
140 145 150
gaa aag ctg acc aac cca gtg ttt gtg ggc tac ctg tgc atc gtg ctg 532
Glu Lys Leu Thr Asn Pro Val Phe Val Gly Tyr Leu Cys Ile Val Leu
155 160 165
ctc atg ctg ctg ctg ctc atc ttc tgg atc gcg ccg gcc cat ggg ccc 580
Leu Met Leu Leu Leu Leu Ile Phe Trp Ile Ala Pro Ala His Gly Pro
170 175 180 185
acc aac atc atg gtc tac atc agc atc tgc tcc ttg ctg ggc agt ttc 628
Thr Asn Ile Met Val Tyr Ile Ser Ile Cys Ser Leu Leu Gly Ser Phe
190 195 200
acc gtg cct tcc acc aag ggc atc ggg ctg gcg gcc caa gac atc ttg 676
Thr Val Pro Ser Thr Lys Gly Ile Gly Leu Ala Ala Gln Asp Ile Leu
205 210 215
cat aac aac ccg tcc agt cag aga gcc ctc tgc ctg tgc ctg gta ctc 724
His Asn Asn Pro Ser Ser Gln Arg Ala Leu Cys Leu Cys Leu Val Leu
220 225 230
ctg gcc gtg ctc ggc tgc agc atc atc gtc cag ttc agg tac atc aac 772
Leu Ala Val Leu Gly Cys Ser Ile Ile Val Gln Phe Arg Tyr Ile Asn
235 240 245
aag gcg ctg gag tgc ttc gac tcc tcg gtg ttc ggg gcc atc tac tac 820
Lys Ala Leu Glu Cys Phe Asp Ser Ser Val Phe Gly Ala Ile Tyr Tyr
250 255 260 265
gtc gtg ttt acc acg ctg gtc ctg ctg gcc tca gcc atc ctc ttc cgg 868
Val Val Phe Thr Thr Leu Val Leu Leu Ala Ser Ala Ile Leu Phe Arg
270 275 280
gag tgg agc aac gtg ggc ctg gtg gac ttc ttg ggg atg gcc tgt gga 916
Glu Trp Ser Asn Val Gly Leu Val Asp Phe Leu Gly Met Ala Cys Gly
285 290 295
ttc acg acc gtc tcc gtg ggg att gtc ctt ata cag gtg ttc aaa gag 964
Phe Thr Thr Val Ser Val Gly Ile Val Leu Ile Gln Val Phe Lys Glu
300 305 310
ttc aat ttc aac ctt ggg gag atg aac aaa tct aat atg aaa aca gac 1012
Phe Asn Phe Asn Leu Gly Glu Met Asn Lys Ser Asn Met Lys Thr Asp
315 320 325
tagattgcaa taggagcttg gatggttcga ggaataggca ttggaggtgg tttctggccg 1072
tgattggatg tgaagtagaa gaggtcctcg atcatggtgt tagaattgac tggatagtaa 1132
caggtggtct ggtggatagc ggggagcatg gctcagcacc agagcagagg cccagccagc 1192
cctctgcagc ccaaacgtcc ccaacggttg cctggcacca tctctctctg atgagacgaa 1252
tctcattttc atttccatta acctggaagc tttcatgaat attctcttct tttaaaacat 1312
tttaacatta tttaaacaga aaaagatggg ctctttctgg ttagttgtta catgatagca 1372
gagatatttt tacttagatt actttgggaa tgagagattg ttgtcttgaa ctctggcact 1432
gtacagtgaa tgtgtctgta gttgtgttag tttgcattaa gcatgtataa cattcaagta 1492
tgtcatccaa ataagaggca tatacattga attgttttta atcctctgac aagttgactc 1552
ttcgaccccc acccccaccc aagacatttt aatagtaaat agagagagag agaagagtta 1612
atgaacatga ggtagtgttc cactggcagg atgacttttc aatagctcaa atcaatttca 1672
gtgcctttat cacttgaatt attaacttaa tttgactctt aatgtgtata tgttcttaga 1732
ttagaataat gcaacttcga gtatgcttta atatttcaat attcaagtta caaatgtata 1792
aggcagttag aaataataca gtcacatgtc acttaatgat agggaaacat tctgagaaat 1852
gcattgtaag gtgactttat tgtgtgaaca tcatggagtg cacttataca aacctagatg 1912
ggacacctat gacccaccca ggccagatgg tacagcctgt tgctcctggg ccacacacct 1972
gtacagcatg tgaccgcact gaataccgca ggcaattgta acacagtggt gagtatttgt 2032
gtttacaaac ataggaaagg tacagtaaaa ctatggtatt acaatgttat gggaccaccg 2092
tcatgtaagt ggtatgtctt tgacagaaac atggttacgt ggttcatgac tgtatattca 2152
ctggaagata gtcaagacta aagacacatt agagcaaatt gaccccttta acatgtgatt 2212
attgtccaat taaagacagt tgatttaagt agcatgaggt attattttat ttgtattcga 2272
tctgtgttac ctgggatcca gtatcaaata tatccacatt ctttatcagc aagcattcat 2332
ggccattcag aagaaataaa ttaggtaact tgataataag gctaagtggg agagtacctg 2392
ttcaatagct catatatcga gtaccctgtc atacaggaac aagttaaagg acacaattga 2452
ggttaggcta gcttctacaa attgcaatat gcagtttttg aaagattttc taacaaaaag 2512
ccaataaatg tagccatctc cttgttgttt gcaatggcag agcatcctag agttcctcag 2572
ctaacctctc attatgtgtc ttaaatgcaa aagagccatt aattatgcca gtatttgaat 2632
caaagaggtc attctctgtc tatagtgttc ccatccatgt gttccaaatg ggagcatagc 2692
atgaagtgat gcacatattt caccacggta tcatgtactt catggccagt gttttatctc 2752
agcagggaac tacgccaagt tgaaagatgg ggttgggtaa agtagattag gtgaagtaga 2812
acataaaatt gaatagtacc caattaaagt tcctcagtaa gaaaaaaaat gtgtttttgt 2872
aggcaaaaag aacatttcta aagtctcaag gaatagcttc ctaaagtgtt gagtaaagag 2932
gctaaataaa atgagactag tttaatatag agagaaaaat acctttatgg agtaaacgtg 2992
tacatgatga tcatgggttg tcagtgattt gtgaactgag agcagcaaca acattatttt 3052
ttaaaaatct taaatcctct caatggatgg ttaacaaatg ctcaaagtcc attactcttt 3112
ttattggctc ttgcaggttt tgtgttttat catcagtgct tttagaaatg caggccttaa 3172
cttactgaac tgaactttct gaaaacgtaa tgtagcagta tcaatatact tttgggcata 3232
aaaatagttt cctaggtaag gggtgtgaga tattcaaaga atacatgtgg ctaacaagtg 3292
taatgagaaa gttcatgtgt cacatgaaaa tgatcatgtt tgtgttgcta cagcttttgt 3352
gggaaattta gtttaaaggc agctcttggt gtaccttagt atattttaat ccacaattat 3412
accattgata ctgagaggtg atacccgatg atcttctcta taatattctt agagtaaaac 3472
aaaatctcaa aagtattaat agctcttcta cccttgaagg tgactggtcc tgggacagtt 3532
agaatctttc aggtttacct ctgttcagca gatacttcag taggatacat agcttttctt 3592
ccagtgaaac aaagttcata tcatccattg tttttcaagc acgtgacacc agcctcaaag 3652
taaatgacat gaccagtggt tgaacagtct aattttcaaa tttaatatag agcatataac 3712
ttctgatttg atagtattta ttttaaaaaa ttatgttttc atcattcatt tgaaaatgaa 3772
aaagccccaa agtgagaact ttgggggagg gcctagaaca tggatagatc tcttagtggt 3832
ctttccaaaa gtacatgtac ttgaaatatt ttcattatca tactattctt tgaaaaaaaa 3892
gatgcttact gtatacttgt tttcaagcat cctctaaaat caaaggtttt gatcacaata 3952
tgcagatttc tcttgataga tacttaaata ggctatttct ctcctcttct tgggcaatgc 4012
cttgttttct cctctgaata tttgcatttg aaaggattgc ttcctgttct gctcattgat 4072
caaaggtagg gccaattaag gattctaacc ctaacccagc accacaaagc ccccctggag 4132
catcttcccg gctggcagga ccatgccatc tctgtggaga aggtgctggg gagggaagtc 4192
cttccagtgc cacatggagt gaggccctgc ccatgctggg gactttgggg aggaatttgg 4252
tattctggtg gccttgctca gctctcattg agatcttttc ctatcagaat gttagtgaat 4312
atacttcgca gctctttgtt cagcaataag gaatattctt tcaattcctg ctcttcaagc 4372
caatttacta cacccagttg tctttccaga agttcatccc agcggtaata tgttggtgtt 4432
tgttcttctt tggatttcac atctgttttc tggtagaagt gagcactgtt cacttgtgca 4492
gtcgtcttat tttccttctt cctagatgac tcagctcttt gtaaatgttg tgctcaactt 4552
ctaggggcca gttctagact ttggagatgc agtgtctccc aggtgtgcac ggacacctgg 4612
tccgtggaaa caggtgtgat gggcacaggc tgctgccctt ctgtctggtc gggggattcc 4672
tcttcttcaa gctgctcagc taacccagaa gaggggagag agtactccgg tggttcccag 4732
agcccctccc gttgtgccgc ttcgacctga cacctgctcg atgctgactt aggcttcctg 4792
ccaccaagca ggaaactaga aagagaacat ttcagtgtaa ggtctgttcc cgacagcatg 4852
gattagcttc cgtgttctga agttgttctt ttcatggtgt ctgacaccga gggcgttgtt 4912
cgtccatcag gcgggattgg atggagtctt ggtgttttgc cttctcaggg accaaaaatg 4972
tatcattgac tccttaacag tgaccttcct cccaaggaca tatccgtgtt catttttcat 5032
aggttttact catattcata ggtagattct gttaatgtga gttggaaaga aaagaccaat 5092
ttgtacacca gtcacaccac aagacagttt atcatataaa atacctcaat tttttgtatt 5152
cctcatttcc acctcacaat tgtactggtg atgaatttta agggtctgtc ctttagctta 5212
taggtgatgt ttcacatctg gccagattct tatacctcca ttgtatactt gaaaaggttc 5272
agaattacag gaacagcagt gagaatttgg cccactacca cgactcattt gtttcattca 5332
cattcctcac gtgcaacaac ataattatat tttaagaaaa tgtaactttg ttacatcaaa 5392
atatgttgtc tagtaaaaag ttgatattca gtagaacaag gatcatgtaa ataaacatct 5452
atttcacatg tacccaaaag catttaaaaa gcagaatcca gggcccagag catgagccag 5512
ggaggaggat gtttttcttc ttttctctat ttttccctaa attgtgcaaa cataggtgag 5572
tctcttaacc tttctgtgcc tcagtttttc tacctctaaa ggggtgggat ggttcttcaa 5632
attgtttcta aaacaccggc actttcagca gtgttctggt ggcctgagat gagagcaccg 5692
tgttcagaag tgcctgggag tggcacagtg gaaactccgc ttgcacggac catggagtct 5752
gctcaggacc atgctgtagg acacacagcc tcatgcgctg agaaagcaaa ggaagtgctg 5812
ggtgtaaagt ttgcatgatt ccatgaagct ttagttttcc tttttttgtt ttaaaagaaa 5872
gggttttata tgttctattg taaaatatgg aaattaaaca gggacttcag aaagccgcac 5932
agaaagatca ccttccgatg gtgtgatgtg ctcctgacat tcggccgagg tctgtattct 5992
gaaaaagatt taatggcctg tgaaacacgt ggattctgtt gcactggatt tgtaataaat 6052
gacgctgaac ttcctgcttc caagcagctc aaccctgatg ctgaactgac accaggcgaa 6112
tgtcagggct cccaaaccac tagtgccaaa gggtcatgtt gaaaagttca gaatatttat 6172
ttgtcagaat ataataattg ccccccacct tagtattttt gcactttaca gaaatttaga 6232
tactgttttt cagtggcttg agcgttttgc cttttcaaag gataactatt attttcttga 6292
aaatggaata taatcatgag aggaagaaga tgtaaaaaat gtcaaatgtt gattggttgt 6352
gtaaaagttt tgtcatagac atgtattggg gagcttccaa ttagcataca tagacacatg 6412
tgtcagtggc caagacctgc ttatattttg ctttatagat gtagtcatag catgttgtta 6472
ttgcctcatg taaataaaaa ggctattaag ttttccagta atatttatta atctgtatgt 6532
gttttaaaat aaaataactt atttctagct gaa 6565
<210>2
<211>329
<212>PRT
<213〉homo sapiens (Homo sapiens)
<400>2
Met Gly Thr Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala
1 5 10 15
Gly Glu Gly Ala Arg Ser Pro Ser Pro Ala Ala Val Ser Leu Gly Leu
20 25 30
Gly Val Ala Val Val Ser Ser Leu Val Asn Gly Ser Thr Phe Val Leu
35 40 45
Gln Lys Lys Gly Ile Val Arg Ala Lys Arg Arg Gly Thr Ser Tyr Leu
50 55 60
Thr Asp Ile Val Trp Trp Ala Gly Thr Ile Ala Met Ala Val Gly Gln
65 70 75 80
Ile Gly Asn Phe Leu Ala Tyr Thr Ala Val Pro Thr Val Leu Val Thr
85 90 95
Pro Leu Gly Ala Leu Gly Val Pro Phe Gly Ser Ile Leu Ala Ser Tyr
l00 105 110
Leu Leu Lys Glu Lys Leu Asn Ile Leu Gly Lys Leu Gly Cys Leu Leu
115 120 125
Ser Cys Ala Gly Ser Val Val Leu Ile Ile His Ser Pro Lys Ser Glu
130 135 140
Ser Val Thr Thr Gln Ala Glu Leu Glu Glu Lys Leu Thr Asn Pro Val
145 150 155 160
Phe Val Gly Tyr Leu Cys Ile Val Leu Leu Met Leu Leu Leu Leu Ile
165 170 175
Phe Trp IIe Ala Pro Ala His Gly Pro Thr Asn Ile Met Val Tyr Ile
180 185 l90
Ser Ile Cys Ser Leu Leu Gly Ser Phe Thr Val Pro Ser Thr Lys Gly
195 200 205
Ile Gly Leu Ala Ala Gln Asp Ile Leu His Asn Asn Pro Ser Ser Gln
2l0 215 220
Arg Ala Leu Cys Leu Cys Leu Val Leu Leu Ala Val Leu Gly Cys Ser
225 230 235 240
Ile Ile Val Gln Phe Arg Tyr Ile Asn Lys Ala Leu Glu Cys Phe Asp
245 250 255
Ser Ser Val Phe Gly Ala Ile Tyr Tyr Val Val Phe Thr Thr Leu Val
260 265 270
Leu Leu Ala Ser Ala Ile Leu Phe Arg Glu Trp Ser Asn Val Gly Leu
275 280 285
Val Asp Phe Leu Gly Met Ala Cys Gly Phe Thr Thr Val Ser Val Gly
290 295 300
Ile Val Leu Ile Gln Val Phe Lys Glu Phe Asn Phe Asn Leu Gly Glu
305 310 315 320
Met Asn Lys Ser Asn Met Lys Thr Asp
325
<210>3
<211>21
<212>DNA
<213〉synthetic
<220>
<221>misc_feature
<222>(1)..(21)
<223〉primer P1
<400>3
gtgctgcgcc catttcagtca 21
<210>4
<211>21
<212>DNA
<213〉synthetic
<220>
<221>misc_feature
<222>(1)..(21)
<223〉primer P2
<400>4
gtgccatctc aactcactgc a 21
Claims (8)
1. a NIPA1 transgenation albumen is characterized in that, the 106th amino acids sports arginine in the aminoacid sequence shown in the SEQ ID NO:2.
2. an isolating NIPA1 mutator gene is characterized in that, the described mutain of its coding claim 1.
3. NIPA1 mutator gene as claimed in claim 2 is characterized in that, undergos mutation for the 341st in the nucleotide sequence shown in the SEQ ID NO:1, and its sudden change is selected from:
G→C;
G→A。
4. method that detects individual NIPA1 transgenation, it comprises step: detect this individual NIPA1 gene, transcript and/or albumen, and compare with normal N IPA1 gene, transcript and/or albumen, it is characterized in that, described difference be among the SEQ ID NO:1 the 341st undergo mutation or SEQ ID NO:2 in the 106th undergo mutation.
5. method as claimed in claim 4 is characterized in that, detection be gene or the transcript of NIPA1, and with normal NIPA1 nucleotide sequence (SEQ ID NO:1) comparing difference.
6. method as claimed in claim 5 is characterized in that, described difference is selected from:
The 341st G → C among the SEQ ID NO:1;
The 341st G → A among the SEQ ID NO:1;
The 106th glycine becomes arginine among the SEQ ID NO:2.
7. a test kit that detects the NIPA1 transgenation is characterized in that, it comprises the primer of specific amplification NIPA1 gene or transcript, and described primer is:
Forward primer: SEQ ID NO:3;
Reverse primer: SEQ ID NO:4.
8. test kit as claimed in claim 7 is characterized in that, described sudden change is selected from:
The 341st G → C among the SEQ ID NO:1;
The 341st G → A among the SEQ ID NO:1;
The 106th glycine becomes arginine among the SEQ ID NO:2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310108710 CN1281621C (en) | 2003-11-19 | 2003-11-19 | Method of diagnosing and treating heritage spasm paraplegia using NIPAl gene mutation hot point |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310108710 CN1281621C (en) | 2003-11-19 | 2003-11-19 | Method of diagnosing and treating heritage spasm paraplegia using NIPAl gene mutation hot point |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1618814A CN1618814A (en) | 2005-05-25 |
CN1281621C true CN1281621C (en) | 2006-10-25 |
Family
ID=34758692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310108710 Expired - Fee Related CN1281621C (en) | 2003-11-19 | 2003-11-19 | Method of diagnosing and treating heritage spasm paraplegia using NIPAl gene mutation hot point |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1281621C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005018431A2 (en) | 2003-08-19 | 2005-03-03 | The Regents Of The University Of Michigan | Compositions and methods for detecting and treating neurological conditions |
CN102286629B (en) * | 2011-09-08 | 2013-01-02 | 中南大学湘雅医院 | Hereditary spastic paraplegia gene diagnosis chip |
-
2003
- 2003-11-19 CN CN 200310108710 patent/CN1281621C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1618814A (en) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100340674C (en) | Deaf-related gene mutation and its detecting method | |
CN1281621C (en) | Method of diagnosing and treating heritage spasm paraplegia using NIPAl gene mutation hot point | |
CN1712543A (en) | Quantitative detection of Leber's genetic optic nerve disease | |
CN1958605A (en) | SPG3A gene mutation, encoded production, and application | |
CN1957091A (en) | K-ras oligonucleotide microarray and method for detecting K-ras mutations employing the same | |
CN1170850C (en) | Human angiogenin-like protein and coding sequence and application thereof | |
CN101033487A (en) | Method of detecting KLK1 gene rs5517 polymorphism correlated to primary hypertension | |
CN1303102C (en) | Method for diagnosing and curing alopecia utilizing the Rhor gene of human and rat and the encoding products | |
CN1749415A (en) | Pannonit treatment acute angina pectoris curative effect detection method and test kit | |
CN1809645A (en) | Method for detecting alzheimer's disease | |
CN1292078C (en) | Hepatic carcinoma tissue specific expression genes and use thereof | |
CN1199998C (en) | Human protein with suppression to cancer cell growth and its coding sequence | |
CN1209373C (en) | Human protein with suppression to cancer cell growth and its coding sequence | |
CN1289524C (en) | Human telomerase active inhibitor protein and use thereof | |
CN1170844C (en) | Human macrobiosis-ensuring protein and its coding sequence and application | |
CN1242061C (en) | Short finger gene | |
CN1279185C (en) | Human hepatoma cell expression down-regulated genes and use thereof | |
CN1824776A (en) | Dilatation type cardiomyopathy diagnosis and therapeutic method and reagent used for said method | |
CN1194010C (en) | New human protein with the function of inhibiting cancer cell growth and its coding sequence | |
CN1182245C (en) | Brachydactyly and body height associated gene | |
CN1329064A (en) | Novel human protein with expression difference in liver cancer tissue and its code sequence | |
CN1690221A (en) | Method and kit for detecting susceptibility of cholelithiasis | |
CN1155613C (en) | Human tumor associated gene in 1-zone 3-band 3-subband of short arm of human chromosome No.17 and its coding protein | |
CN1570138A (en) | Cholelithiasis susceptibility detecting method and kit | |
CN1199994C (en) | New human protein with cancer cell growth inhibiting function and its coding sequence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061025 Termination date: 20161119 |
|
CF01 | Termination of patent right due to non-payment of annual fee |